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Objectives: Peripheral arterial disease is associated with significant adverse out-
comes, especially in patients with critical limb ischemia (CLI; stages III and IV). At 
6 months, the risk of amputation is 35%, and mortality 20%. In patients unsuitable 
for interventional therapy, treatment with prostanoids may help reduce the risk of 
adverse outcomes. We aimed to assess the average cost of alprostadil (prostaglan-
din E1) as treatment for patients with CLI compared with lumbar sympathectomy 
from the perspective of The Mexican Social Security Institute (IMSS). MethOds: 
In a clinical trial, alprostadil and lumbar sympathectomy showed similar response 
rates (Petronella P, et al. Nutr Metab Cardiovasc Dis 2004;14:186–92).Therefore, we 
conducted a cost minimization analysis based on the direct medical costs of alpros-
tadil (40 µg twice-daily or 60 µg once-daily) administered over 28 days versus lumbar 
sympathectomy. Relevant costs included acquisition and infusion for alprostadil, 
and surgical procedure besides hospitalization (9 days) for lumbar sympathectomy. 
Unit cost for infusion was assumed to be equivalent to an emergency visit at first 
level of care at IMSS; unit cost of the surgical procedure and standard hospital stay 
(per day) correspond to the official values for these items at the second level of care 
at IMSS. UCB Pharma provided the cost for alprostadil. All costs are in 2013 Mexican 
pesos (MXN; 12.88 MXN = 1 USD, 17.23 MXN = 1 Euro). Results: Costs per patient 
would be lower with both alprostadil 40 µg twice-daily ($59,640) and alprostadil 
60 µg once-daily ($37,884) than with lumbar sympathectomy ($66,084), leading to 
savings of $6,444 (9.8%) and $28,200 (42.7%), respectively. Alprostadil use remained 
cost-saving versus lumbar sympathectomy in most of the scenarios evaluated 
through sensitivity analysis. cOnclusiOns: These results suggest alprostadil is a 
cost saving intervention when compared with lumbar sympathectomy for patients 
with CLI from the Mexican public health care perspective.
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Objectives: The objective of this pharmacoeconomic evaluation was to determine 
whether apixaban, compared to warfarin, dabigatran and rivaroxaban in patients 
suitable for vitamin K antagonists (VKA), or to aspirin in VKA-unsuitable patients, 
is a cost-effective treatment for the prevention of stroke or systemic embolism (SE) 
in adult patients with non-valvular atrial fibrillation (AF) with one or more risk fac-
tors. MethOds: A Markov model was constructed consisting of 18 health states, 
using a 6-week cycle length and a lifetime time horizon. Baseline characteristics were 
taken from a 2011 GPRD study. Clinical inputs were derived from a network meta-anal-
ysis of the efficacy and bleeding outcomes from the three warfarin-controlled trials 
ARISTOTLE, RE-LY and ROCKET-AF, and the single aspirin-controlled trial AVERROES. 
Local unit costs and utility data were assigned to the appropriate model health states 
to calculate total Quality-Adjusted Life Years (QALYs) and costs. Univariate and proba-
bilistic sensitivity analyses (PSA) were conducted. Results: Apixaban was associated 
with an ICER vs warfarin of € 11,087. Against the less-commonly used anti-coagulants, 
apixaban was cost-effective against each at the € 45,000 willingness-to-pay thresh-
old. Apixaban provided more QALYs than all other therapies. Compared to warfarin, 
apixaban produced savings in avoided cost of stroke, intracranial haemorrhage, INR 
monitoring, and bleeding. Apixaban was cost-effective across all patient subgroups 
of INR control (centre Time in Therapeutic Range) and CHADS2stroke risk categories 
1 and 2. One-way sensitivity analyses, scenario analyses, and probabilistic sensitivity 
analyses confirmed that the findings were robust to changes in key parameters. The 
probability that apixaban was the most cost-effective therapy at a willingness-to-
pay threshold of € 45,000 per QALY was 93% and 100% in the VKA-suitable and VKA-
unsuitable populations, respectively. cOnclusiOns: Apixaban can be considered 
cost-effective for the prevention of stroke and SE in people with non-valvular AF, at 
a threshold of € 45,000/QALY, under standard decision rules.
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Objectives: Stroke prevention is the main goal in treating patients with atrial 
fibrillation (AF). Treatment with anticoagulants, such as vitamin-K antagonists 
(VKAs; e.g. warfarin and cumarines), was demonstrated to be an effective strat-
egy. However, even though VKAs are the current standard therapy recommended 
by different guidelines, the significant risk of bleeding and the requirement for 
a regular monitoring are limiting its use. Apixaban is a novel oral anticoagulant 
(NOAC) associated with significantly lower hazard rates for stroke/systemic embo-
lism, major hemorrhage and discontinuations, compared to VKAs. This study evalu-
ated the cost-effectiveness (CE) of apixaban compared to VKAs in the base-case 
analysis and alternatively to other NOACs for stroke prevention in non-valvular 
AF patients in The Netherlands. MethOds: A global Markov model developed by 
United BioSource Corporation was modified to reflect the use of oral anticoagulants 
in The Netherlands. The model used efficacy data from a published indirect treat-
ment comparison of NOACs and cost data from Dutch costing studies as inputs. 
Following health states were included in the model: non-valvular AF, primary and 
recurrent ischemic and hemorrhagic stroke, systemic embolism, myocardial infarc-
tion, intracranial hemorrhage, other major and non-major bleedings, treatment 
patients suffering from chronic heart failure is a highly cost-effective health tech-
nology in the Polish setting, according to the criterion defined in Reimbursement 
Law. Robustness of this finding is demonstrated by the fact that cost-effectiveness 
is retained even at a price double vs base-case.
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Objectives: Large randomized clinical trials (RCT) evidenced the benefits of statins 
in reducing major cardiovascular events in patients with established coronary heart 
disease (CHD). These multinational trials are likely to provide internally valid evi-
dence. Cost-effectiveness analysis based on single trials costs and effects are common 
and represent the potential net benefit of an intervention in a well-controlled environ-
ment. The aim of this study is to systematically review the cost-effectiveness studies 
based on statins single trials in patients with previous CHD. MethOds: We searched 
to identify all literature relating to the cost-effectiveness of statins in the secondary 
prevention in patients with established CHD. Only studies with the effectiveness data 
extracted from a single RCT and clinical outcomes such as quality assessment, mor-
tality or cardiovascular events rate were included. The cost per QALY was classified 
according to the WHO, following three categories of cost-effectiveness, Highly cost-
effective, Cost-effective and Not cost-effective, adjusted with GDP per capita based 
on purchasing power parity (constant 2005 international USD). Results: Twenty-one 
studies were included in the final analysis, covering a period range from 1996 to 
2009. 7 large RCTs represented the origin of efficacy data. Most of studies assumed 
a full compliance, the Markov models were used in 11 out 21 studies. Time horizon 
ranged from 5 years to time life, with 10 years being the predominant choice. 9 studies 
performed a cost-utility analysis and showed the average cost per QALY, 8 of them 
classified as highly cost-effective and 1 cost-effective. Cost per QALY was sensitive for 
drug price, time horizon and event rates, 6 of this models models worked with com-
posite endpoints. cOnclusiOns: Statins are highly cost-effective in patients with 
CHD when effect size came from single well designed RCTs. Models heterogeneity 
and composite endpoints can decrease the robustness of the results.
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Objectives: It has been suggested that radiofrequency catheter ablation could take 
priority over antiarrhythmic drugs as first-line treatment of paroxysmal AF, due to 
better efficiency, and fewer serious side effects. The objective of this study was to 
evaluate the cost-effectiveness of treating paroxysmal atrial fibrillation with radi-
ofrequency catheter ablation as first-line treatment. MethOds: A decision-analytic 
Markov model was developed to study long-term effects and costs of catheter abla-
tion compared to antiarrhythmic drugs as first-line treatment. Results: Small, 
positive clinical effects were found in the overall population, a gain of an average 
0.06 quality-adjusted life years (QALYs) to an incremental cost of € 3033, resulting in 
an incremental cost-effectiveness ratio of € 50 570/QALY. However, the incremental 
cost-effectiveness ratio of a 45-year-old patient was approximately € 3434/QALY, 
while a 65-year-old costs € 108 937 per QALY. cOnclusiOns: Radio-frequency cath-
eter ablation as first-line treatment is a cost-effective strategy for younger patients 
with paroxysmal atrial fibrillation. However, the cost-effectiveness of using catheter 
ablation as first-line therapy in older patients is uncertain, and in most of these 
cases antiarrhythmic drug therapy should be attempted before catheter ablation.
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Objectives: Portugal is facing an economic crisis that demands a tight control over 
all hospitals’ expenditures, namely with medical devices, whose market price is not 
yet regulated or documented. This study aims to describe the number and value of 
the Active-Implantable Cardiac Devices (AICD) bought by Portuguese hospitals in 
2011, as well as to quantify potential savings that can be obtained shifting utilisation 
from higher to lower prices. MethOds: In February 2012, 42 hospitals were asked 
by INFARMED – National Authority of Medicines and Health Products, IP, about the 
number, type and value of the AICD acquired, using an ad-hoc developed software. 
Potential savings analysis was performed at two levels: AICD sub-groups (according 
to Portuguese Medical Device Nomenclature) and individual device reference. Within 
each level, three cost-minimization scenarios were conceptualized based on the 
minimum price reported (scenario 1), the average between the average price and 
the minimum one (scenario 2) and the average price (scenario 3). Results: During 
2011, 73.8% of the hospitals enrolled (n= 31) bought AICD, comprising 16,815 devices, 
at a cost of 40,217,411 euros. In numbers, the most common AICD were pacemakers 
(44.8%), whereas cardioverter-defibrillators were related to a higher expenditure 
ratio (51.5% of total cost). Based on the AICD sub-groups analysis, the potential sav-
ings were 14.5 million euros in scenario 1 (44.1% of total cost), 7.4 million euros in 
scenario 2 (22.5%) and 1.8 million euros in scenario 3 (5.3%). Following this scenario 
order, the device reference approach estimated savings of 6.2 million euros (18.8%), 
3.4 million euros (10.3%) and 1.1 million euros (3.3%), respectively. cOnclusiOns: 
Significant potential savings were found, being greater when analysing AICD sub-
groups, assuming equal efficiency and safety for all devices within these clusters. 
Despite scenario 1 higher savings, scenario 2 seems the most realistic and feasible, 
when trying to accomplish a sustainable health care system.
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and literature sources. Two price scenarios were evaluated, one in which the sutureless 
valve is sold at the double, and one at the triple price of its comparator. Future costs and 
outcomes are discounted at a yearly 3.5% rate. Results: In the first cost scenario, the 
model predicts that on average MiAVR with Perceval S instead of traditional sutured 
valves in FS would yield incremental 0.29 LYs (0.20 QALYs) and savings for about 3,000 
€ and 3,250 £, in France and UK, respectively. In the second cost scenario, Perceval S 
in MiAVR still remains dominant, with savings for 550 € and 740 £, in France and UK, 
respectively. Deterministic threshold analysis indicates that the sutureless valve would 
retain acceptable cost-effectiveness (at willingness-to-pay thresholds of 30,000€ and 
20,000£ per QALY) as long as its price does not exceed 5.6 and 4.9 times that of the 
traditional valve, in France and UK, respectively. cOnclusiOns: The sutureless valve 
in combination with MiAVR offers the opportunity to improve outcomes in isolated 
AVR at a reduced cost to the third party payers.
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in Chinese Adults Aged 45 And AboVe
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Serum total and LDL cholesterol levels are high (13.9% for borderline high LDL- choles-
terol) and increasing in China. Hyperlipidemia is a main risk factor for cardiovascular 
and cerebrovascular diseases. Screening is one of the effective prevention methods; 
however, there has been no appraisal of the cost-effectiveness of blood lipid screen-
ing in China. Objectives: To determine the cost-utility of blood lipid screening and 
subsequent interventions versus no screening for the prevention and treatment of 
hyperlipidemia and its complication. MethOds: Cost utility analysis based on a 
Markov model was conducted for a cohort of Chinese adults aged 45 and abovefrom 
screening to death. Published clinical trials and epidemiological studies retrieved from 
electronic bibliographic databases; supplementary data obtained from CVD patients 
survey in China. Markov model simulated the long term effects of screening and no 
screening strategies from the aspects of cost and effectiveness. The model assumed a 
30 year time horizon, and costs and benefits were discounted at 5%. The willingness-
to-pay threshold is ¥100,000/QALY. Sensitivity analyses were conducted to evaluate 
assumptions of the model and to identify which model inputs had most impact on the 
results. Results: Estimated costs for each quality adjusted life year (QALY) gained 
among no screening population were ¥6325.8, with cumulative costs of ¥77112 and 
cumulative utility of 12.19, and ¥5783.5 for screened population with cumulative costs 
of ¥72178 and cumulative utility of 12.48, respectively. The results showed the blood 
lipid screening was associated with increased QALY and potentially cost-saving as 
compared with no screening. Sensitivity analyses demonstrated robustness of the 
results. cOnclusiOns: Based on this Markov model, blood lipid screening is likely 
to be cost-effective option compared with no screening for the prevention and treat-
ment of hyperlipidemia and its complication among Chinese aged 45 and above.
PCV108
Cost-effeCtiVeness of drug-eluting stents Versus bAre metAl 
stents in egyPtiAn diAbetiC PAtients
ElSisi G., Ragab S., Ashraf R., Elmahdawy M.
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Objectives: Cost-effectiveness of Drug eluting stents (DES) versus bare metal stents 
(BMS) in Egyptian diabetic patients with chronic coronary artery disease from a 
patient perspective was evaluated over a time horizon of 3 years. MethOds: A cohort 
Markov process model with five health states: stent, coronary artery bypass surgery 
(CABG), non-fatal myocardial infarction (MI), percutaneous coronary intervention 
(PCI) and death was derived from published data. The transition probabilities from the 
index procedure to death, MI, PCI, and CABG were derived from an updated, previously 
published meta-analysis of RCTs comparing DES with BMS in patients with coronary 
artery disease. Relative risk reduction, restenosis risks, mortality rates, utilities were 
derived using published sources. Direct Medical costs were obtained from 4 top-rated 
cardiology hospitals in Egypt. All costs and effects were discounted at 3.5% annually. 
All costs were reported in Egyptian pounds of the financial year 2013. Deterministic 
sensitivity analysis was conducted. Results: In the overall population, total costs for 
DES and BMS were 20,664 EGP and 11,957 EGP respectively. Total QALYs for DES and 
BMS were 2.26 and 2.05 respectively. The incremental cost-effectiveness ratio (ICER) 
for DES versus BMS was 41,616 EGP/QALY. DES is cost effective because it is less than 
3 times GDP/capita in Egypt (57,566 EGP). Results between DES and BMS were most 
sensitive to the Mortality rate of both DES and BMS. cOnclusiOns: World Health 
Organization recommends that interventions that cost more than 3 times GDP/capita 
for one Disability Adjusted Life Year (DALY) avoided should not be reimbursed. Despite 
DALY is different from QALY but we can assume that they are similar to be able to put 
a value on the outcome. DES represents a good value for money compared to BMS in 
Egyptian diabetic patients with chronic coronary artery disease.
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Objectives: Using statins in primary prevention is controversial given the low event 
rate and the difficulty to identify patients who really benefit. Coronary calcium score 
has been identified as a strong predictor of cardiovascular events, being recom-
mended for risk stratification in intermediate risk individuals. This study aims to 
assess, from the Portuguese societal perspective, the cost-utility of determining coro-
nary calcium score to guide the use of statins in individuals with elevated C-reactive 
protein and low LDL cholesterol. Three strategies are compared: no treatment, test 
and treat accordingly, and treat every patient with rosuvastatin 20mg. MethOds: 
discontinuations and death. Main outcomes were quality adjusted life years (QALY) 
and costs. Univariate and probabilistic sensitivity analyses (PSA) were conducted on 
the incremental cost-effectiveness ratio (ICER). Results: In the base-case analysis, 
apixaban treatment compared to VKAs has an ICER well below an informal mini-
mal willingness-to-pay threshold of € 20,000/QALY for The Netherlands (i.e. around 
€ 7,000/QALY). PSA showed that the results of the base-case analysis were quite 
robust. Potentials exist for apixaban to be dominant over the other NOACs, rivaroxa-
ban and dabigatran depending on hazard ratios, risks for complications and local 
price levels. patients in The Netherlands. cOnclusiOns: In patients with AF, we 
found apixaban to be a cost-effective option in The Netherlands, compared to VKAs.
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A soCietAl PersPeCtiVe Cost-utility AnAlysis of riVAroxAbAn 
ComPAred with enoxAPArin sodium in PAtients undergoing totAl hiP 
or totAl knee rePlACement surgery
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Objectives: Several cost-effectiveness analyses exist that compare rivaroxaban 
with enoxaparin sodium as thrombosis prophylaxis in patients undergoing total 
hip replacement (THR) or total knee replacement (TKR) surgery. However, none of 
these refers to a societal perspective, and thus indirect costs have so far not yet 
been included. The objective of this research was to conduct a cost-utility analysis 
from the German societal perspective, based on a life-time horizon. MethOds: A 
decision-tree was used to calculate the short term consequences of treatmentby 
classifying whether subjects experienced a deep a vein thrombosis, a pulmonary 
embolism, a major bleeding, death due to the surgery, or no event. Furthermore, 
we designed a Markov model to quantify the long-term consequences. The main 
health effect was based on the RECORD 1 and RECORD 3 trials. A semi-micro simu-
lation approach was applied to reflect the age and gender distribution of the target 
population. Probabilistic, deterministic and structural sensitivity analyses were per-
formed to assess the robustness of the results. Results: Rivaroxaban dominated 
enoxaparin sodium in the case of TKR. This dominance was robust within sensitivity 
analysis. In contrast, the point estimate of the cost-effectiveness ratio in the case of 
THR was € 867,018 per quality-adjusted life year (QALY). However, there was a wide 
variation within the probabilistic sensitivity analysis: the dots were substantially 
scattered over three quadrants of the cost-effectiveness plane. Compared to previ-
ous analyses, the selection of effectiveness data seems to have a significant impact 
of the results. cOnclusiOns: Rivaroxaban was found to dominate enoxaparin 
sodium after TKR, whereas the evidence regarding THR is unclear. Results were 
similar to previous analyses from the third-party payer perspective.
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Cost-effeCtiVeness modelling of AlternAtiVe serViCe designs
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Objectives: To estimate the cost-effectiveness of home telemonitoring (TM) or 
structured telephone support (STS) strategies versus usual care for adults recently 
discharged (within 28 days) after a heart failure (HF) exacerbation in England and 
Wales. MethOds: A Markov model was used to evaluate a) STS via human to 
machine (HM) interface, b) STS via human to human (HH) contact, and c) TM, against 
d) usual care. Given heterogeneity in the interventions, cost-effectiveness analysis 
was performed using bottom up costing scenarios regarding costs of devices, moni-
toring and medical care to deal with alerts. Costs and quality adjusted life years 
(QALYs) over a 30 year (patient lifetime) horizon were estimated based on monthly 
probabilities of death and monthly risks of hospitalisations (HF-related complica-
tions or other causes) estimated from clinical effectiveness parameters computed 
using a network meta-analysis of randomised controlled trials. Results: Base case 
monthly costs per patient were: £27 for usual care, £119 for STS HM, £179 for STS HH 
and £175 for TM. TM was the most cost-effective strategy in the scenario using these 
base case costs. Compared with usual care, TM had an estimated incremental cost 
effectiveness ratio (ICER) of £9,552/QALY, whereas STS HH had an ICER of £63,240/
QALY against TM. STS HM was dominated by usual care. Probabilistic sensitivity 
analysis (PSA) showed 44% chance of TM being cost-effective at a willingness to 
pay threshold of £20,000 per QALY, with STS HH 36%, STS HM 18% and usual care 
2%, respectively. Scenario analyses performed using higher costs of usual care, 
higher costs of STS HH and lower costs of TM do not substantially change the con-
clusions. cOnclusiOns: Cost-effectiveness analyses suggest TM was an optimal 
strategy in most scenarios, but there is considerable uncertainty in relation to clear 
descriptions of the interventions and robust estimation of costs.
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Objectives: Mini-invasive aortic valve replacement (MiAVR) has several advantages 
over full sternotomy (FS), mainly less surgical trauma, decreased blood loss, lower 
mortality and faster recovery. Perceval S is an aortic valve which is implanted without 
need for suturing and a collapsed profile, thus allowing a significant reduction of cross-
clamping times, an independent risk factor for worse outcomes, allowing to expand 
the pool of operable patients with MiAVR. MethOds: A patient-level simulation model 
fully coded in WinBugs was updated and extended to predict lifetime effectiveness 
and costs of isolated AVR procedures associated with this new valve in France and 
UK, as compared to traditional valve implants, from the cost perspective of the third 
party payer. Unit costs and health state-specific utilities were retrieved from official 
